May 11, 2020
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine
May 07, 2020
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Apr 30, 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Apr 16, 2020
Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
Apr 06, 2020
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
Mar 23, 2020
Soligenix and University of Hawai i at M noa Initiate Work on Novel Coronavirus Vaccine for COVID-19
Feb 27, 2020
Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform
Feb 13, 2020
FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning
Feb 03, 2020
Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis
Jan 30, 2020
Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference
Jan 14, 2020
Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
Dec 18, 2019
Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Dec 12, 2019
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
Nov 18, 2019
Soligenix to Present at the PCG Spotlight Series Conference
Nov 12, 2019
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
Nov 06, 2019
Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference
Oct 24, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
Oct 03, 2019
Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
Aug 28, 2019
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
Aug 15, 2019
Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications